FGF2 and inflammatory bowel disease: Immunohistochemical analysis indicated that rectal administration of HEP-Ag-BSA markedly reduced myeloperoxidase activity and interleukin-6 (IL-6) expression, while simultaneously enhancing syndecan-1 and basic fibroblast growth factor (bFGF) immunoreactivity, in comparison to the dextran sulfate sodium (DSS)-induced IBD models [11].